ADDRESSING THE CORE CHALLENGE OF CANCER TREATMENT

There is no silver bullet to treat cancer patients at large. Cancer is not a single disease, but rather a group of diseases. In total there are more than 100 different types of cancers which are dynamically expressed in each patient.

Identifying combinations therapies at different dosages are necessary when searching the best cancer treatment. However, Humans nor Big Data AI/ML can efficiently solve for large and complex set of predictions.

About Us

KYAN’s mission is to BRIDGE THE CANCER CARE GAP by advancing revolutionary technologies

OUR SOLUTIONS

Intelligent drug-dose optimization of combinations for those who truly need it

Truly Personalized Medicine Solution

Using ex-vivo drug sensitivity experiments, KYAN supports physicians identify safe and effective treatments for individual cancer patients

Efficient Biopharma R&D Services

From target prioritization to biomarker identification, KYAN is the only platform that effectively efficiently solves large & complex searches for drug devel0opment

News

KYAN Therapeutics Announces Collaboration with Institute of Molecular and Cell Biology for Accelerated Drug Discovery and Development of Nucleic Acids

Aug 23 kyanetics

We have entered into a collaboration with Institute of Molecular and Cell Biology to discover and develop next-generation nucleic acid […]

KYAN Therapeutics Exclusively Licenses Small Molecule

Sep 24 kyanetics

We acquired the rights to develop promising HDAC inhibitors for AI-powered cancer drug development. Read more in our press release: […]

AI Platform Aids Treatment for Relapsed Lymphoma

Jul 25 kyanetics

An application of our technology was recently featured in The Straits Times. You can read more about it here: https://www.straitstimes.com/singapore/ai-platform-aids-treatment-for-relapsed-lymphoma.

RECENT PUBLICATIONS

2020

Bioengineering and Translational Medicine

IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Science

Artificial intelligence in cancer therapy

Blood Cancer Journal

Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma

2019

Advanced Therapeutics

Harnessing Artificial Intelligence to Optimize Long‐Term Maintenance Dosing for Antiretroviral‐Naive Adults with HIV‐1 Infection

SLAS Technology

Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine

2018

Advanced Therapeutics

Artificial Intelligence: Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform

Science Translational Medicine

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)

Our Team Members

Hugo Saavedra

CEO

Lisa Chow

COO / General Counsel

Masturah Rashid

Head, Research and Development

Edward Chow

Scientific Co-founder

Chih-Ming Ho

Scientific Co-founder

Dean Ho

Scientific Co-founder

Our Advisors

Andreas Voss

Chief Medical Advisor

Phal Singh

Chief Financial Advisor

Rasha Kandil

Chief Regulatory Advisor

Wee Joo Chng

Director at National University Cancer Institute, Singapore

Carl Firth

Founder and CEO at ASLAN Pharmaceuticals

Katherine Wang

Project Director, Oncology at Ascendis Pharma A/S

Aleidy Silva

Lead Field Applications Scientist at Berkeley Lights

Partners and Collaborators

Contact Us

We are passionate about what we do and if you have any interesting projects and ideas to share with us, feel free to send us an email or drop us a message in the contact form to the right.

Address: 83 Science Park Drive, The Curie, #02-03/04, Singapore 118258

Phone: +65 9730 2672

Email: press@kyantherapeutics.com

Name *

Email *

Subject *

Message